<DOC>
	<DOCNO>NCT02305355</DOCNO>
	<brief_summary>Assess efficacy safety Omacor® 4g statin treatment lower TG level subject type 2 Diabetes combine hyperlipidemia</brief_summary>
	<brief_title>Efficacy Safety Prescription Omega-3 Fatty Acid Added Stable Statin Therapy Patients With Type 2 Diabetes Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>LDLC &lt; 100mg/dL , TG &gt; 150mg/dL , patient statin treatment least 6 week prior randomization . Type 2 Diabetes HbA1c ≤ 10.0 Type 1 Diabetes Patients PPAR gamma agonist therapy Patients acute MI , Unstable angina within 6 month History malignant tumor within 2 year Women pregnant , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>